Skip to main content
. 2023 Jun 30;11(7):1183. doi: 10.3390/vaccines11071183

Figure 6.

Figure 6

Age influence on anti-RBD IgA and IgG and anti-spike IgG serum levels for each collection time for the BNT162b2, ChAdOx1 nCoV-19, and CoronaVac vaccines. Serum from individuals immunized with BNT162b2, ChAdOx1 nCoV-19, and CoronaVac was collected at times T2 (1 month after application of the second dose), T3 (4–6 months after application of the second dose or pre-third dose), and T4 (1 month after the application of the third dose). The evaluation of the influence of age on the production of anti-RBD IgA (A–C) and IgG (D–F) and anti-spike IgG (G–I) antibodies was performed by means of the enzyme immunoassay (ELISA) described in the methods section. Individuals in the population were segregated into three age groups: from 18 to 30 years old (ChAdOx1 nCoV-19: n = 20; BNT162b2: n = 15; CoronaVac: n = 4), from 31 to 50 years old (ChAdOx1 nCoV-19: n = 5; BNT162b2: n = 4; CoronaVac: n = 11), and over 50 years old (ChAdOx1 nCoV-19: n = 8; BNT162b2: n = 8; CoronaVac: n = 3). The results are expressed by the index calculated between the ratio: mean optical density (OD) of the sample/cutoff (S/CO-Signal/Cutoff). Each point represents a single individual. The end of the bar indicates the median value and the horizontal bars above and below the median indicate the 95% confidence interval. The Kruskal–Wallis test was used to compare the indices of induced antibodies. Statistical significance was adopted for p < 0.05.